You are here: Industry Insights > AstraZeneca

News List

AstraZeneca’s Calquence phase III ASCEND trial meets positive result biospectrumasia
May 09, 2019
Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) in the US, Brazil, the UAE, and Qatar, and is being developed for the treatment of CLL and other blood cancers.
AZ, Daiichi HER-2 drug shows promise in mid-stage trial pharmatimes
May 09, 2019
AstraZeneca has announced that its joint HER2-targeting antibody drug conjugate (ADC) with Daiichi Sankyo has met its primary endpoint in a phase II trial.
AstraZeneca, Daiichi Sankyo's trastuzumab deruxtecan hits main goal of Phase II study in refractory HER2-positive metastatic breast cancer firstwordpharma
May 09, 2019
AstraZeneca and Daiichi Sankyo announced Wednesday that a pivotal Phase II study of trastuzumab deruxtecan in patients with refractory HER2-positive metastatic breast cancer met its primary endpoint ...
AstraZeneca’s new formulation tablets receive positive CHMP opinion europeanpharmaceuticalreview
May 07, 2019
AstraZeneca’s new formulation tablets receive positive CHMP opinion.
FDA Approves Qternmet XR drugs
May 06, 2019
FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes.
AstraZeneca forms drug discovery alliance with BenevolentAI pharmaceutical-technology
May 05, 2019
AstraZeneca has partnered with artificial intelligence (AI) company BenevolentAI to develop treatments for chronic kidney disease and idiopathic pulmonary fibrosis.
AstraZeneca and Transgene to develop cancer drug candidates pharmaceutical-technology
May 05, 2019
AstraZeneca has signed an agreement with French biotech company Transgene to develop cancer drug candidates using genetically engineered vaccinia viruses.
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery worldpharmanews
May 05, 2019
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery.
AstraZeneca dumps Amgen-partnered drug after midphase fail fiercebiotech
April 28, 2019
AstraZeneca has dropped (PDF) Amgen-partnered autoimmune drug prezalumab from its pipeline. The action follows the failure of the anti-B7RP1 antibody in a midphase Sjöogren’s syndrome trial.
AstraZeneca’s Lynparza gets EC approval for breast cancer pharmaceutical-technology
April 23, 2019
The European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer in adults.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page